FDA places partial halt on vantictumab trial

|By:, SA News Editor

As expected, the FDA places a partial clinical hold on OncoMed's (OMED +8%) Phase 1 clinical trial for vantictumab. On Friday, the company announced a voluntary halt to patient enrollment and dosing in response to higher-than-expected adverse events. It is working with bone experts and investigators to assess the events and develop revised trial protocols.